The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Bubba - the MMAPp product is not ready. I think it is probably just us at this point and we have passed P1 which is the feasibility study. P2 is the clinical validation which takes 4 more weeks. We should get an RNS then which will give performance figures
Mains pros are that its a lot cheaper by a factor of 4 or 5 than PCR and that it can be used as a prognostic tool as well.
The bid is for a market engagement event.
The workflow of the ms programme mentioned in bid is 4 weeks clinical validation followed by 12 weeks scale validation followed by 4 weeks for NHS scale up. So if all goes well BAMS should be operating at high scale in NHS by April. But it should be bringing in decent revenue by december end through its use for scale validation, assuming the initial clinical validation goes well
My guess would be
1. BAMS and LFD become preferred tests for expansion of lab and quick testing and that they get large contracts and large manufacturing partners enabling them to hit profits several x mcap
2. As a multi billion pound company with a war chest they make a strategic acquisition to enable future diagnostics work to go from conception to customer with greater speed and seamlessness. A big beast like Abingdon or a smaller one like ODX would be options. Would leave current management and other staff and facilities largely in place.
2. Significant additional progress on the diagnostic business with further new tests for covid and beyond
3. significant developments in its partnerships
4. Excellent progress in the clinic with the upcoming trial which combined with the war chest encourages further trials to be teed up.
Sp in the range of 10 to 20 quid
BAMS validation is scheduled to be 6 weeks total. I think we are about 4 weeks in. May be leak of some early data or a leak of Government plans for BAMS use.
Could be re-rate an big buying. Could be info leaking about LFD tech transfer or about plans for its clinical evaluation.
Could be Moderna related.
So many options precisely because there is so much potential for big positive happenings.
That's all true except the bit about huge delay. Its happening fast. Not as fast as the ceo initially implied in late spring, but still within the reset parameters he gave in september, with the recent tweet confirming all going well.
Both the **** testing developments and the breathalyser test are potentially great. The latter is not just future proofed by its potential to be used on other viruses but very much in the mix now if the performance turns out to be good. Plastics waste aside, LFDs are very useful in reducing r and Avacta's turn out to be especially good due to affimers. But getting manufacturing volume is a challenge and so there will be a great shortage of quick results tests for a period of potentially years, notwithstanding what may speculatively be possible on the vaccine front. At the right price and performance this will be one of the approaches to fulfil the demand gap and could do extremely well.